June 20, 2016

LAST DAY to Pre-Register tomorrow!
We hope you can join us for the NRG Oncology Semiannual Meeting, July 14-16, 2016 at the Sheraton Dallas Hotel in Dallas, TX. The hotel room block reservation deadline and the meeting pre-Registration deadline is Tuesday, June 21, 2016! Please pre-register online for this meeting by June 21, 2016. Registering onsite at the meeting will incur an additional $50 fee. Registration and meeting information is available on the NRG Oncology website.

Summer Symposium - “Endometrial Cancer: The Future of Targeted Therapy”
Thursday, July 14, 2016, 8:00 am-2:30 pm
Program Description

Scientific Session - NRG Oncology Research Review
Friday, July 15, 2016, 8:00 am-10:00 am

Dr. Marvella Ford to speak at special NRG Oncology Workshop on Cultural Competency in Clinical Trials
This workshop, on Friday, July 15, at 11 am, is designed for NRG Oncology research investigators, nurses, CRAs, and support staff to understand the role cultural competency plays in clinical trials. With recruitment of patients from underrepresented minority groups in clinical trials at less than 1%, there is an opportunity to reduce this gap in health disparity! Don't forget to register.

NRG-BN001: Additional funding now available for sites participating in the advanced imaging sub-study. Details on the CTSU Funding Sheet.

RTOG 0929: Amendment 12; Version Date: June 3, 2016

NRG-HN002: Amendment 2; Version Date: May 24, 2016

NRG-HN002: OPEN Eligibility Checklist 1 has been revised and is available at https://www.ctsu.org/public/. Use the revised version date June 15, 2016 immediately.

NRG-HN002: New form added - Modified Barium Swallow is available at https://www.ctsu.org/public/.

Vision Tree Webinar
The next VTOC training session will be face to face at the NRG semiannual meeting July 14, 2016 at 1 pm CDT. The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, and NRG-HN002. Space is limited so register now and reserve your seat. The next webinar training is scheduled for August 10, 2016.

Safety updates and an IB update have been issued for GOG legacy studies. For details, please see the GOG Weekly Mailing page.

An IB update has been issued for NSABP legacy studies. For details, please see the NSABP Members’ Area or the E-mail Distributions page and the CTSU website.

Safety updates have been issued for the following NRG Oncology studies:
Ipilimumab: NRG-G003
Nivolumab: NRG-GY002, NRG-GY003
-For NRG-GY002 and NRG-GY003 safety reports, please see the protocol page on the NRG Oncology website for details.

In observance of Independence Day, Biologics, Inc. will be closed on Monday, July 4, 2016. Regular business hours will resume on Tuesday, July 5, 2016. If you have questions, please contact our Clinical Research Services team at 800-693-4906, or via email at clinicaltrials@biologicsinc.com.

Independence Day holiday closure information for the NRG Oncology Operations Offices, Statistics and Data Management Centers (SDMCs), and Biospecimen Banks is posted on the NRG Oncology website under "News."

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

Song N, Pogue-Geile KL, Gavin PG, Yothers G, Kim SR, Johnson NL, Lipchik C, Allegra CJ, Petrelli NJ, O'Connell MJ, Wolmark N, Paik S. Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. JAMA Oncol. 2016 Jun 6. doi: 10.1001/jamaoncol.2016.2314. [Epub ahead of print] PubMed PMID: 27270348. Read more
Presented concurrently at the ASCO 2016 Annual Meeting during the Clinical Science Symposium Gastrointestinal (Colorectal) Cancer session.
Accompanying editorial: Grothey A, Sargent DJ. Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine. JAMA Oncol. 2016 Jun 6. doi: 10.1001/jamaoncol.2016.2304. [Epub ahead of print] PubMed PMID: 27273467. Read more

Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2016 May 23. pii: JCO658153. [Epub ahead of print] PubMed PMID: 27217446. Read more

Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M. Reply to F. Felix et al and M.F. Fay et al. J Clin Oncol. 2016 Jun 13. pii: JCO680926. [Epub ahead of print] PubMed PMID: 27298403. Read more

Wolmark N, Mamounas EP, Baehner FL, Butler SM, Tang G, Jamshidian F, Sing AP, Shak S, Paik S. Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. J Clin Oncol. 2016 May 23. pii: JCO626630. [Epub ahead of print] PubMed PMID: 27217450. Read more

Please note the following upcoming meeting and abstract submission deadline dates.

Upcoming Meetings
Multinational Association of Supportive Care in Cancer (MASCC), Jun 23-25, 2016, Adelaide, Australia
American Brachytherapy Society (ABS), Jun 27-29, 2016, San Francisco, CA
American Head & Neck Society (AHNS), Jul 16-20, 2016; Seattle, WA

Upcoming abstract submission deadlines
European Society for Medical Oncology (ESMO), Oct 7-11, 2016, Copenhagen, Denmark; meeting abstract submission deadline Aug 23, 2016 LBA

Society of Clinical Research (SOCRA), Sep 30-Oct 2, 2016; Montreal, QC, Canada; due to publications committee Jul 15, 2016; meeting abstracts submission deadline Jul 29, 2016

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103